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Highlights 
 Selective and total gut decontamination differentially affect the gut microbiota 
 Selective decontamination results in a microbiota with high Bacteroides abundance 
 Stringent bacterial eradication results in a variable residual microbiota 
 Probiotics use after HSCT does not aid colonization by the administered bacteria 
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Graphical abstract
 
 
Abstract 
Bloodstream infections and Graft-versus-Host disease (GvHD) are common complications 
after hematopoietic stem cell transplantation (HSCT) procedures, associated with the gut 
microbiota which acts as a reservoir for opportunistic pathogens. Selective gut 
decontamination (SGD) and total gut decontamination (TGD) during HSCT have been 
associated with a decreased risk of developing these complications after transplantation. 
However, since studies have shown conflicting results, the use of these treatments remain 
subject of debate. In addition, their impact on the gut microbiota is not well studied. The aim 
of this study was to elucidate the dynamics of the microbiota during and after TGD and to 
compare these to the dynamics of SGD. In this prospective, observational, single-center study, 
fecal samples were longitudinally collected from nineteen children eligible for allogenic 
HSCT (TGD n=12, SGD n=7), weekly during hospital admission and monthly after 
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discharge. In addition, fecal samples were collected from three family stem cell donors. Fecal 
microbiota structure of patients and donors was determined by 16S rRNA gene amplicon 
sequencing. Microbiota richness and diversity markedly decreased during SGD and TGD and 
gradually increased after cessation of decontamination treatment. During SGD, gut microbiota 
composition was relatively stable and dominated by Bacteroides, while it showed high inter- 
and intra-individual variation and low Bacteroides abundance during TGD. In some children, 
TGD allowed the genera Enterococcus and Streptococcus to thrive during treatment. A gut 
microbiota dominated by Bacteroides was associated with increased predicted activity of 
several metabolic processes. Comparing the microbiota of recipients and their donors 
indicated that receiving a stem cell transplant did not alter the patient’s microbiota to become 
more similar to that of its donor. Overall, our findings indicate that SGD and TGD affect gut 
microbiota structure in a treatment-specific manner. Whether these treatments affect clinical 
outcomes via interference with the gut microbiota needs to be further elucidated. 
 
Keywords  
Gut decontamination, Microbiota, Hematopoietic stem cell transplantation, Graft-versus-Host 
disease, Pediatrics 
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Introduction 
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for 
patients with various life-threatening diseases such as high-risk hematological malignancies, 
acquired or inborn bone marrow failure syndromes, severe immune deficiencies, and 
hemoglobinopathies. Graft-versus-Host disease (GvHD) is a severe and frequent complication 
of HSCT, characterized by severe organ damage due the initiation of an immune response of 
donated tissue (the graft) towards host tissue. The exact pathophysiology of GvHD is not 
known. Antigen-presenting cells, cytokines and T-lymphocytes play a central role in the 
pathogenesis of GvHD
1
. GvHD is considered to be initiated by a cascade of inflammation 
caused by tissue damage and translocation of intestinal microbial components
1
.  
Mouse experiments revealed that antibiotic exposure before HSCT was a risk factor 
for the development of GvHD
2
. The bacterial community remained heterogeneous in mice 
without GvHD, whereas it became severely restricted in mice with GvHD
2
. Also, in adult 
HSCT patients with GvHD, a loss of diversity of the gut microbiota over time occurred in 
contrast to patients without GvHD
2
. Patients that later on developed GvHD had a higher 
Bray-Curtis dissimilarity index, interpreted as greater microbial ‘chaos’, early after HSCT, 
before the onset of clinical symptoms
2
. These findings indicate a role for the gut microbiota in 
GvHD pathogenesis. 
Complete suppression of the intestinal microbiota by the use of non-absorbable 
antibiotics has been shown to prevent the initiation of the inflammatory cascade mediated by 
translocation of microbial compounds and the subsequent occurrence of acute GvHD
3-5
. 
Based on this concept, our pediatric HSCT program routinely applies total gut 
decontamination (TGD), starting at least one week before stem cell infusion, in all T cell 
replete HSCT patients. If the risk for GvHD is considered low, as in the case of an identical 
twin as donor or an HLA-identical donor with serotherapy, the patients receive selective gut 
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decontamination (SGD) as infection prevention during the neutropenic phase. SGD aims at 
selectively eliminating and suppressing Gram-negative bacterial pathogens and yeasts from 
the intestinal microbiota. In contrast to studies supporting gut decontamination treatment in 
the course of HSCT, several studies have associated gut decontamination with an increased 
risk for GvHD
6,7
, rendering their application subject of debate. Many hospitals practice gut 
decontamination according to their (inter)national guidelines with own adjustments
8
. Gut 
decontamination procedures therefore vary between centers, which may in part explain the 
discrepancies regarding GvHD outcomes.  
It is incredibly relevant to improve our understanding of the effect of gut 
decontamination treatments on HSCT outcomes, and to elucidate underlying mechanisms 
(such as treatment-specific modulation of the gut microbiota). Although some microbiota 
analyses have been performed in patients undergoing SGD
2,9
, it is currently unresolved to 
what extent the intestinal microbiota is eliminated by TGD. In addition, limited studies 
focused on microbiota composition during HSCT in children
10,11
. The aim of the current 
observational, single-center study was to get insight into the gut microbiota structure during 
and after SGD and TGD in the course of pediatric allogenic HSCT.   
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Materials and Methods 
Subjects  
For this prospective, observational, single-center study, all children (<18y) eligible for an 
allogeneic HSCT at the Leiden University Medical Center between January and December 
2015 were asked to participate in the MiCaDO (Microbioom en Calprotectin in Darm 
Onderzoek) study. Indications for allogeneic stem cell transplantation were either a 
malignancy (ALL and AML: n=7), primary immunodeficiency (n=3), myelodysplastic 
syndrome or Fanconi anemia (n=5) or hemoglobinopathy (sickle cell disease and ß-
thalassemia: n=4). Conditioning regimens were chosen based on international protocols with 
local adaptations, decided upon after group discussion for each patient individually. No ex-
vivo T cell depletion was applied. Twelve patients received TGD from 10 days before 
transplantation, until engraftment or 21 days post-transplantation, whichever occurred latest. 
TGD consists of oral piperacillin/tazobactam and oral amphotericin B
4
. The efficacy of TGD 
was tested by weekly stool culture. In case persistent growth of aerobic Gram-negative 
bacteria or yeasts was observed, additional non-absorbable antimicrobials were added based 
on susceptibility testing. Recolonization of the intestine after TGD was aided by the oral 
administration of Symbiolact® (SymbioPharm, Germany), which contains Lactobacillus 
acidophilus, Lactobacillus paracasei and Bifidobacterium lactis. In case of a haplo-identical 
peripheral T cell depleted stem cell graft with low T cell counts, HLA-identical donor with 
serotherapy or a HLA-identical cord blood graft, the chance of the occurrence of GvHD is 
considered low. In these instances, no TGD was given. Seven patients received SGD instead, 
consisting of oral polymyxin/neomycin and oral amphotericin B following a similar schedule 
as TGD, but without the oral administration of Symbiolact®.  
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Ethical considerations  
This study was conducted according to the principles of the Declaration of Helsinki, last 
amended October 2013 (www.wma.net) and in accordance with the Medical Research 
Involving Human Subjects Act (WMO) and was approved by the medical ethical committee 
of the Leiden University Medical Center, accession number P14.266. All children and/or their 
parents provided written informed consent for stool collection and analysis. 
 
Fecal sample collection 
Fecal samples were collected 10 days before admission, then weekly during admission for 
transplantation, and monthly thereafter up to 6 months after transplantation. This timeline 
corresponds to sampling during the 4 weeks of decontamination treatment, up till 6 months 
thereafter. A total of 120 samples were collected for analysis (Figure S1). In addition, a fecal 
sample was collected from three family stem cell donors. Fecal samples were stored at -80°C 
within 24 hours after collection. 
 
16S rRNA gene sequencing  
DNA was extracted from feces using the Quick-DNA™ Fecal/Soil Microbe Miniprep Kit 
(ZymoResearch, CA, USA) according to manufacturer instructions. Quality control, library 
preparation and sequencing were performed by GenomeScan B.V. (Leiden, The Netherlands) 
using the NEXTflex™ 16S V4 Amplicon-Seq Kit (BiooScientific, TX, USA) and the 
Illumina 2500 system (rapid mode, paired-end, 250bp). Raw sequencing data is available in 
the European Nucleotide Archive (http://www.ebi.ac.uk/ena) under study accession 
PRJEB28845. 
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Sequencing data was analyzed using the QIIME software package v1.9.1 applying Uclust and 
the Greengenes database for OTU picking and taxonomic classification
12,13
. The obtained 
OTU table was filtered for OTUs with a number of sequences less than 0.005% of the total 
number of sequences
14
. To account for variation between samples’ total number of reads, 
rarefaction to 116076 reads per sample was applied. Microbiota composition profiles for each 
sample are shown in figure S2. Microbiota richness and diversity were determined by the 
Chao1 and PD whole tree indexes, respectively. To determine the variation in bacterial 
community profiles within children over time, weighted and unweighted UniFrac distances 
were determined. This indicates the dissimilarity in microbiota composition between samples 
over time from each individual and thereby illustrates overall microbiota stability. To study 
(dis)similarities in microbiota composition and relate changes in microbiota composition to 
clinical data, principal component analysis (PCA) and redundancy analysis (RDA) were 
performed using the Canoco multivariate statistics software v5
15
. For RDA analysis, variables 
included in the original model were type of decontamination, time since start of 
decontamination, age, gender, and meropenem, ciprofloxacin, vancomycin, ceftazidime and 
azithromycin use. These factors were considered significant when the false discovery rate 
corrected p-value was below 0.05. Microbiota profiles were tested for similarity between 
donors, between recipients, between donors and their corresponding recipients and between 
donors and non-corresponding recipients via Spearman correlation. For this purpose, 
recipients’ fecal samples collected around 100 days after transplantation were used to allow 
for microbiota development and stabilization. Functionality of the microbiota was predicted 
using PICRUSt 1.0.0.
16
, which was presented as relative KEGG orthology profiles. These 
profiles were imported in Canoco multivariate statistics software v5 for principal component 
analysis to visualize functional (dis)similarities between samples
15
.  
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Results 
A total of 19 patients and 3 donors were included in this study. Baseline characteristics, 
underlying disease and type of gut decontamination are outlined in Table 1. Of the 19 
patients, 12 received TGD, consisting of oral piperacillin/tazobactam and oral amphotericin 
B, whereas the other seven received SGD with oral polymyxin/neomycin and oral 
amphotericin B. Ten children completed 6 months of follow-up, 2 patients died during 
follow-up, 7 developed bloodstream infection (BSI), and 4 developed GvHD (Table 1). 
 
Selective and total gut decontamination decrease microbiota richness and diversity 
To determine the effect of SGD and TGD on gut microbiota structure, 16S rRNA gene 
amplicon sequencing was performed on longitudinally collected fecal samples from each 
patient giving insight in the temporal dynamics of bacterial microbiota composition, richness 
and diversity. During the first two weeks after start of SGD and TGD, microbiota richness 
(chao1) and diversity (phylogenetic diversity) showed high inter-individual variation (Figure 
1a,b). When richness and diversity where higher at start, a temporal decrease could be 
observed until the point was reached, after four weeks of decontamination, where all 
children’s microbiota was low in richness and diversity (Figure 1a,b). Richness and diversity 
gradually increased after discontinuation of SGD and TGD, its pace and pattern being 
individual-specific, which is partly illustrated by the large distinction between the boxplot’s 
mean, minimum and maximum values (Figure 1c,d). 
 
SGD, but not TGD, allows a stable gut microbiota dominated by Bacteroides 
To determine (dis)similarities in microbiota composition and relate these to clinical data, 
ordination analyses were performed. This revealed that type of decontamination treatment 
was the main driver of variation in microbiota composition between all samples (9.1%), 
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followed by time since start of decontamination treatment (5.3%) and meropenem use (4.1%) 
(Figure 2a, Table S1). The difference in microbiota composition between patients receiving 
TGD or SGD was mainly associated with the abundance of the Bacteroides genus (Figure 
2a,b). The microbiota of patients receiving SGD was characterized by high abundance of 
Bacteroides, which showed a trend of increasing abundance during decontamination 
treatment, while decreasing after treatment cessation (Figure 3a, Figure S3a). In contrast, a 
marked decrease in Bacteroides abundance was observed during TGD (Figure 3a). In 
addition, the gut microbiota of some patients receiving TGD almost solely consisted of 
Enterococcus or Streptococcus during treatment, which was not seen in patients receiving 
SGD (Figure 3b,c, Figure S3b,c). After cessation of TGD, the recolonization attempt via oral 
administration of Symbiolact®,  which contains Lactobacillus acidophilus, Lactobacillus 
paracasei and Bifidobacterium lactis, did not affect the abundance of lactobacilli and 
bifidobacteria.  
Microbiota composition was more stable in patients receiving SGD compared to TGD, 
as indicated by lower within patient UniFrac distances, showing that microbiota composition 
was less dissimilar between samples over time in patients receiving SGD than in patients 
receiving TGD (p=0.046, Figure 4a). Apart from the high abundance of Bacteroides, a stable, 
but individual-specific, microbiota composition was observed during and after SGD (Figure 
S2a). However, in one child (subject A), microbiota composition varied greatly over time and 
was generally dominated by one specific bacterial taxa being either Bacteroides, 
Staphylococcus or Enterobacteriaceae, most certainly due to the occurrence of several 
infections and therefore extensive exposure to various broad-spectrum antibiotics. The 
microbiota of patients receiving TGD was not characterized by a specific stable profile, but 
showed high intra- and inter-individual variation (Figure S2b). This instability was most 
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prominent during decontamination treatment, and became less apparent after cessation of 
decontamination treatment and during follow-up (Figure 4b). 
 
Receiving HSCT does not alter the recipient’s microbiota to become more similar to that of 
its donor. 
Fecal microbiota composition was determined in three stem cell donors around time of 
transplantation. Fecal microbiota composition varied among the three donors (Figure S2c). 
One donor was dominated by Prevotella (45%), the second donor was dominated by 
Prevotella and Lactococcus (21% and 38% respectively), while the third donor’s microbiota 
composition was more evenly distributed with high abundance of various taxa including 
Bifidobacterium, Faecalibacterium and Lachnospiraceae (16%, 15% and 15% respectively). 
Bacteroides was a prominent member of the bacterial community in all three donors, covering 
9%, 10% and 14% respectively. Despite varying microbiota composition between stem cell 
donors, community richness and diversity were similar and in line with adult microbiota 
characteristics (Figure 1a,b). 
Given the intimate interplay between the immune system and the gut microbiota, we 
wondered if transplantation of a donor immune system, through HSCT, would result in a 
more donor-like microbiota in recipients. Therefore, Spearman correlations between donor 
and recipient microbiota composition profiles were determined. Correlations between 
microbiota composition of 1) donors as a group, 2) recipients as a group, 3) donors and its 
corresponding recipients, and 4) donors and its non-corresponding recipients were 0.78, 0.66, 
0.59 and 0.59, respectively. This indicates that receiving a stem cell transplant did not alter 
the patient’s microbiota to become more similar to that of its donor. Instead, a situation is 
created in which HSCT recipient’s microbiota is variable between patients, but more similar 
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to one another than to donors, reflecting the individual-specific consequences of HSCT 
procedures on microbiota composition.   
 
Prediction of microbiota’s function 
To get insight in what the decontamination treatment-associated differences in microbiota 
composition could mean for functioning of the microbiota, we predicted the microbiotas’ 
metagenome, and thereby its potential functional traits, using 16S rRNA-based taxonomy. 
This revealed that a gut microbiota dominated by Bacteroides, as observed during SGD, was 
associated with increased activity in several metabolic processes, including energy 
metabolism and glycan biosynthesis and metabolism (Figure S4). Microbiota composition of 
patients receiving TGD was associated with increased processes involved in membrane 
transport, transcription, signal transduction and xenobiotics biodegradation and metabolism 
(Figure S4). 
 
Graft-versus-Host Disease 
Four patients in this cohort developed GvHD grade 1 or more, of which two patients received 
SGD (subjects A and C) and two received TGD (subjects N and Q) (Table 2). Although our 
study set-up does not allow to conclusively link microbiota to GvHD, due to low GvHD 
prevalence and lack of samples at the time of GvHD onset, we present the chronology of gut 
microbiota composition and GvHD onset (Figure S5). Subject A and C both followed the 
‘typical’ SGD dynamics before onset of GvHD, with Bacteroides being a dominant member 
of the community (Figure S5). Microbiota composition of subjects N and Q are conflicting, 
with a predominance of Enterococcus species in subject N, and great bacterial diversity in 
subject Q (Figure S5). Overall, characteristics of the bacterial community as observed in 
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patients developing GvHD, were also observed in patients who did not develop this severe 
complication (Figure S2).  
 
Discussion 
The gut microbiome has been implicated in various health outcomes, including immune 
recovery after HSCT and onset of infections and GvHD
17
. It is therefore important to 
understand the effect of gut decontamination treatments on gut microbiota structure. Here, we 
studied the dynamics of the gut microbiota in an unique cohort of children receiving selective 
or total gut decontamination as part of HSCT procedures.  
In this cohort, microbiota richness and diversity decreased considerably while receiving TGD 
or SGD, and tended to increase at an individual-specific pace after cessation of 
decontamination treatment. Although SGD and TGD affected microbial community richness 
and diversity in a similar manner, they differently affected microbiota composition. During 
TGD, Bacteroides markedly decreased, most certainly driven by oral administration of 
piperacillin/tazobactam
18,19
. High abundance of Bacteroides, as observed during SGD, has 
been suggested beneficial in times of gut microbiota disturbance, due to their capacity to drive 
microbiota reconstruction via interspecies interaction through the degradation of 
polysaccharides
10,20,21
. In our study, functional prediction indeed revealed that a gut 
microbiota dominated by Bacteroides is associated with increased processes involved in 
energy and glycan metabolism. Alterations in the microbiotas’ functional capacities may be 
particularly relevant in light of HSCT outcomes, e.g. immune recovery and onset of infections 
and GvHD
17,22,23
. A higher Bacteroides abundance pre-transplantation, has been associated 
with increased propionate levels and decreased risk of acute GvHD in children
10
. In light of 
this, low Bacteroidetes abundance has been used as incentive for autologous fecal microbiota 
transplantation in patients who have undergone allo-HSCT
24
.  
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In addition to the differentially abundant Bacteroides, the genera Enterococcus and 
Streptococcus thrived in some children during TGD, which was not observed in any subject 
receiving SGD. A marked increase in enterococci, streptococci and members of the 
Enterobacteriaceae family post-transplantation has been previously reported
10,11,25
. 
Outgrowth and predominance of a selected number of bacterial genera might possess a health 
risk to the patients, as acute GvHD has been associated with bloodstream infections caused by 
enteric bacteria, particularly by enterococci
25-27
. However, absolute quantification of 
enterococci would be required to determine whether these bacteria actually outgrew. 
Microbiota composition was highly variable between patients and within patients over time. 
Such instability may be a consequence of low bacterial load as a result of the TGD regimen
28
. 
Administration of Symbiolact® after TGD, upon engraftment, did not aid colonization of 
Lactobacillus and Bifidobacterium species. It, however, remains unclear whether 
Symbiolact® is beneficial by other means, like quicker recovery of bacterial diversity overall 
or improved clinical outcomes.   
Considering the gut microbiota in the course of HSCT, most studies so far focused on 
microbial predictors or modifiers of GvHD, most commonly in adult populations
2,10,11,25,29-31
. 
Overall, these studies revealed that profound disturbances of gut microbiota composition and 
diversity, as a result of HSCT and associated regimens (e.g. gut decontamination), are 
associated with acute GvHD. Although specific organisms have been suggested as protective 
(e.g. Blautia, Faecalibacterium and Ruminococcus), or harmful (e.g. Enterococcus, 
Streptococcus, Escherichia and Enterobacter), their exact contribution regarding GvHD 
needs to be further elucidated. 
Using conventional culturing techniques, our group previously showed that successful 
TGD is associated with a reduced risk of GvHD in children
4,5
. Through the application of next 
generation sequencing, however, we herein show that bacterial signatures remain, being of 
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highly variable composition and with a remarkable decrease of anaerobic Bacteroides. The 
elimination of beneficial bacteria, and its potential consequences for clinical outcomes, should 
be considered when applying the TGD regimen in the course of HSCT. The low incidence of 
GvHD in this cohort, in combination with the lack of samples around time of GvHD 
diagnosis, prevented to study the link between gut decontamination regimen, microbiota 
composition and GvHD. In this cohort, 37% of patients developed bloodstream infection. 
Interestingly, this occurred in a higher percentage of patients receiving SGD (57%) than TGD 
(25%).  
Taking into account the gut microbiota of a small number of stem cell donors, we 
observed that despite the intimate interplay between the immune system and the gut 
microbiota, a stem cell transplant did not result in the recipient’s microbiota becoming more 
similar to that of its donor. So far, research regarding the microbiota of stem cell transplant 
donors is limited. High bacterial diversity in transplant donors has been associated with 
decreased acute GvHD risk
32
, but a study using murine models reported no association 
between the donor microbiota and GvHD severity.  
This is, to our knowledge, the first report on gut microbiota dynamics in children 
receiving two different gut decontamination regimens as infection and GvHD prophylaxis 
during HSCT. Despite the prospective set-up and longitudinal sampling, the relatively small 
subject size, lack of pre-decontamination samples and diversity in underlying diseases and 
other clinical characteristics makes further investigation warranted. In addition, microbiota 
composition analysis via 16S-rRNA gene amplicon sequencing, as herein, does not provide 
species-level information nor insight in actual microbiota functioning, which could improve 
the understanding of the host-microbiota relationship. Nevertheless, our findings give a good 
indication of the differential effect of SGD and TGD on the gut microbiota during pediatric 
HSCT. Whether these gut decontamination treatments affect clinical outcomes via the 
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interference with the gut microbiota still needs to be elucidated. In addition, further research 
should focus on clinical implication and possibilities to stimulate microbiota recovery after 
HSCT. 
 
Acknowledgments 
We are indebted to the participants of this study and to the nursing staff for their help with 
sample collection. We acknowledge the assistance from drs. Elisabeth M. Terveer and the 
valuable input on the structure of this manuscript by dr. Wiep Klaas Smits. We acknowledge 
the ESCMID Study Group for Host And Microbiota Interaction (ESGHAMI) for stimulating 
discussion about this topic.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 18 
References 
 
1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 
373(9674): 1550-61. 
2. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota 
following allogeneic bone marrow transplantation. J Exp Med 2012; 209(5): 903-11. 
3. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of 
intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin 
alone on the development of acute graft-versus-host disease after marrow transplantation in 
patients with hematologic malignancies: final results and long-term follow-up of an open-
label prospective randomized trial. Blood 1999; 93(10): 3267-75. 
4. Vossen JM, Guiot HF, Lankester AC, et al. Complete suppression of the gut 
microbiome prevents acute graft-versus-host disease following allogeneic bone marrow 
transplantation. PLoS One 2014; 9(9): e105706. 
5. Vossen JM, Heidt PJ, van den Berg H, Gerritsen EJ, Hermans J, Dooren LJ. 
Prevention of infection and graft-versus-host disease by suppression of intestinal microflora 
in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect 
Dis 1990; 9(1): 14-23. 
6. Gjaerde LK, Schmidt M, Sengelov H. Gut decontamination during allogeneic 
hematopoietic stem cell transplantation and the risk of acute graft-versus-host disease. Bone 
Marrow Transplant 2018; 53(8): 1061-4. 
7. Routy B, Letendre C, Enot D, et al. The influence of gut-decontamination prophylactic 
antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic 
stem cell transplantation. Oncoimmunology 2017; 6(1): e1258506. 
8. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious 
complications among hematopoietic cell transplantation recipients: a global perspective. Biol 
Blood Marrow Transplant 2009; 15(10): 1143-238. 
9. Benus RF, Harmsen HJ, Welling GW, et al. Impact of digestive and oropharyngeal 
decontamination on the intestinal microbiota in ICU patients. Intensive Care Med 2010; 
36(8): 1394-402. 
10. Biagi E, Zama D, Nastasi C, et al. Gut microbiota trajectory in pediatric patients 
undergoing hematopoietic SCT. Bone Marrow Transplant 2015; 50(7): 992-8. 
11. Lane JP, Stewart CJ, Cummings SP, Gennery AR. Gut microbiome variations during 
hematopoietic stem cell transplant in severe combined immunodeficiency. J Allergy Clin 
Immunol 2015; 135(6): 1654-6. 
12. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-
throughput community sequencing data. Nat Methods 2010; 7(5): 335-6. 
13. DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S 
rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006; 
72(7): 5069-72. 
14. Bokulich NA, Subramanian S, Faith JJ, et al. Quality-filtering vastly improves 
diversity estimates from Illumina amplicon sequencing. Nat Methods 2013; 10(1): 57-9. 
15. Šmilauer P, Lepš J. Multivariate analysis of ecological data using CANOCO 5: 
Cambridge University Press; 2014. 
16. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of 
microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013; 31(9): 
814-21. 
17. Zama D, Biagi E, Masetti R, et al. Gut microbiota and hematopoietic stem cell 
transplantation: where do we stand? Bone Marrow Transplant 2017; 52(1): 7-14. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 19 
18. Hedberg M, Nord CE, Bacteria ESGoARiA. Antimicrobial susceptibility of 
Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003; 9(6): 475-88. 
19. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the 
susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States 
from 1997 to 2004. Antimicrob Agents Chemother 2007; 51(5): 1649-55. 
20. Fischbach MA, Sonnenburg JL. Eating for two: how metabolism establishes 
interspecies interactions in the gut. Cell Host Microbe 2011; 10(4): 336-47. 
21. Lee SM, Donaldson GP, Mikulski Z, Boyajian S, Ley K, Mazmanian SK. Bacterial 
colonization factors control specificity and stability of the gut microbiota. Nature 2013; 
501(7467): 426-9. 
22. Lane JP, Stewart CJ, Cummings SP, Gennery AR. Functional changes in gut 
microbiota during hematopoietic stem cell transplantation for severe combined 
immunodeficiency. J Allergy Clin Immunol 2016; 138(2): 622-5 e3. 
23. Romick-Rosendale LE, Haslam DB, Lane A, et al. Antibiotic Exposure and Reduced 
Short Chain Fatty Acid Production after Hematopoietic Stem Cell Transplant. Biol Blood 
Marrow Transplant 2018. 
24. Taur Y, Coyte K, Schluter J, et al. Reconstitution of the gut microbiota of antibiotic-
treated patients by autologous fecal microbiota transplant. Sci Transl Med 2018; 10(460). 
25. Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool 
microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is 
associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-
versus-host disease. Biol Blood Marrow Transplant 2014; 20(5): 640-5. 
26. Levinson A, Pinkney K, Jin Z, et al. Acute gastrointestinal graft-vs-host disease is 
associated with increased enteric bacterial bloodstream infection density in pediatric 
allogeneic hematopoietic cell transplant recipients. Clin Infect Dis 2015; 61(3): 350-7. 
27. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in 
patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 
55(7): 905-14. 
28. Vandeputte D, Kathagen G, D'Hoe K, et al. Quantitative microbiome profiling links 
gut community variation to microbial load. Nature 2017; 551(7681): 507-11. 
29. Golob JL, Pergam SA, Srinivasan S, et al. Stool Microbiota at Neutrophil Recovery Is 
Predictive for Severe Acute Graft vs Host Disease After Hematopoietic Cell Transplantation. 
Clin Infect Dis 2017; 65(12): 1984-91. 
30. Jenq RR, Taur Y, Devlin SM, et al. Intestinal Blautia Is Associated with Reduced 
Death from Graft-versus-Host Disease. Biol Blood Marrow Transplant 2015; 21(8): 1373-83. 
31. Simms-Waldrip TR, Sunkersett G, Coughlin LA, et al. Antibiotic-Induced Depletion 
of Anti-inflammatory Clostridia Is Associated with the Development of Graft-versus-Host 
Disease in Pediatric Stem Cell Transplantation Patients. Biol Blood Marrow Transplant 2017; 
23(5): 820-9. 
32. Liu C, Frank DN, Horch M, et al. Associations between acute gastrointestinal GvHD 
and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and 
donors. Bone Marrow Transplant 2017; 52(12): 1643-50. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Tables 1 
 2 
Table 1. Subject characteristics. 3 
 4 
 
Decon 
 
Subject 
 
Age 
 
Gender 
 
Indication 
 
Donor type 
 
SC source 
 
SC donor 
BSI 
episodes* 
Causative 
organism** 
Systemic 
Antimicrobials 
 
GvHD 
SGD*** A 16 Male Leukemia MUD 10/10 PBSC - 7 Staphylococcus epidermidis (5), 
Klebsiella pneumoniae (4), 
Klebsiella ornitholytica (1), 
Enterococcus faecalis (1), 
Candida orthopsilosis (1) 
Van, Caz, Vcz GIT/Skin 
SGD B 16 Male Leukemia HLA-identical Bone marrow Donor 2 1 Staphylococcus epidermidis (1) Vcz - 
SGD C 17 Male Benign hematology HLA-identical Bone marrow - - - Van, Caz Skin 
SGD D 8 Male Benign hematology HLA-identical Bone marrow - - - Amx, Van, Caz - 
SGD E 8 Female Benign hematology Haploidentical PBSC - 2 Streptococcus mitis (1), 
Staphylococcus aureus (1), 
Klebsiella pneumoniae (1), 
Acinetobacter baumannii (1) 
Van, Caz - 
SGD F 10 Male Benign hematology HLA-identical Bone marrow Donor 3 1 Actinomyces oris (1) Van, Caz - 
SGD G 11 Male MDS HLA-identical Bone marrow Donor 1 - - Van, Caz - 
TGD H 3 Female Leukemia MUD 10/10 Bone marrow - 1 Lachnoanaerobaculum orale (1) Van, Caz, Vcz - 
TGD I 14 Female Leukemia MUD 10/10 Bone marrow - - - Van, Caz, Vcz - 
TGD J 7 Female MDS MUD 10/10 Bone marrow - - - Van, Caz - 
TGD K 15 Female MDS MUD 9/10 Bone marrow - - - Amx, Van, Caz - 
TGD L 15 Female MDS HLA-identical Bone marrow - - - - - 
TGD M 1 Female PI MUD 6/10 Cord blood - 1 Bacillus simplex (1) Van, Vcz - 
TGD N 13 Female Leukemia MUD Bone marrow - - - Van, Caz, Vcz Skin 
TGD O 11 Male PI HLA-identical Bone marrow - - - Van, Caz - 
TGD P 1 Female PI MUD 9/10 Bone marrow - - - Amx, Van, Caz - 
TGD Q 13 Male Benign hematology MUD 10/10 Bone marrow - 3 Moraxella (2), 
Microbacterium paraoxydans (2), 
Streptococcus mitis (1), 
Staphylococcus epidermidis (1) 
Amx, Van, Caz Skin 
TGD R 1 Male Leukemia MUD 10/10 Bone marrow - - - Amx, Van, Caz - 
TGD S 12 Female MDS MUD 10/10 Bone marrow - - - Van, Caz - 
* Episode is defined as a two weeks period. ** Number between brackets indicates the amount of sepsis episodes the organism was identified in. *** Patient A received SGD instead of TGD due to 5 
the presence of multidrug-resistant organisms in the gut. ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, Amx: Amoxicillin, BSI: Bloodstream infection, Caz: Ceftazidime, Decon: 6 
gut decontamination, GvHD: graft-versus-host disease, HLA: Human leukocyte antigen, MDS: Myelodysplastic syndrome, MUD: Matched unrelated donor, PBSC: peripheral blood stem cell, PI: 7 
Primary immunodeficiency, SC: stem cell, Van: Vancomycin, Vcz: Voriconazole. 8 
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Table 2. Graft-versus-Host Disease characteristics. 
 
 
Subject 
 
Decontamination 
Onset (days since start 
decontamination) 
Onset (days  
since HSCT) 
 
Organ 
 
Grade 
A SGD 65 54 GIT/Skin 3 
C SGD 26 16 Skin 1 
N TGD 57 47 Skin 2 
Q TGD 49 39 Skin 2 
GIT: gastrointestinal tract, HSCT: hematopoietic stem cell transplantation.  
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Figure legends 
 
Figure 1. Chao1 richness and phylogenetic diversity of the bacterial community during 
(A, B) and after (C, D) decontamination treatment. Boxes show minimum, maximum and 
mean values. D: Stem cell donors.  
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Figure 2. Redundancy analysis (A) and principal component analysis (B) of the gut 
microbiota composition profiles. Per sample taxonomic profiles at genus level were used to 
generate these plots. Clinical factors significantly explaining microbiota variation are shown. 
The percentage of variation explained by the principal coordinates is indicated on the axis.     
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Figure 3. Temporal dynamics of specific bacterial taxa during decontamination 
treatment. Boxes show minimum, maximum and mean relative abundance. D: Stem cell 
donors. 
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Figure 4. UniFrac distances within children receiving selective or total gut 
decontamination treatment. A. Weighted and unweighted UniFrac distance within children 
based on all available samples. Boxplots show the median, 25th and 75th percentiles, and 
minimal and maximal values. The asterisk indicates a significant difference (p < 0.05) as 
determined via the Kruskal Wallis test with Monte Carlo permutation (10.000x). B. Weighted 
UniFrac distance within children during decontamination treatment (during), during the four 
weeks after cessation of decontamination treatment (after) and during the months of follow-up 
(follow-up). Boxplots show the median, 25th and 75th percentiles, and minimal and maximal 
values. Statistical analysis was not performed since UniFrac distances could not be 
determined for all subjects at each time period, resulting in insufficient amount of data points 
for statistical testing.  
